NLRP5 and neoplasm: Other substantial amplifications included 19q13.43 in 24/118 tumours (20%), containing NLRP5, ZNF444 and ZNF787; 5q35.2 in 27/118 tumours (23%), containing GPRIN1 immediately adjacent to CDHR2 which may moderate contact inhibition of epithelial cell growth25; and 5q35.3 in 26/118 tumours (22%) containing LTC4S and SQSTM1. The latter encodes p62, a mediator of autophagy influencing tumorigenesis, malignant growth and resistance to therapy26.